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DESIGN PAPER

Assessment of primary prevention patients receiving
an ICD – Systematic evaluation of ATP: APPRAISE ATP
Claudio D. Schuger, MD,* Kenji Ando, MD,† Daniel J. Cantillon, MD,‡
Pier D. Lambiase, MD, PhD,x Lluis Mont, MD,k Bo Young Joung, MD,{
Darren Peress, MD,# Patrick Yong, MSEE,** Nicholas Wold, MS,**
James P. Daubert, MD††
From the *Henry Ford Heart & Vascular Institute, Detroit, Michigan, †Kokura Memorial Hospital,
Kitakyushu, Japan, ‡Cleveland Clinic, Heart and Vascular Institute, Cardiac Electrophysiology and
Pacing, Cleveland, Ohio, xSt. Bartholomew’s Hospital, London, United Kingdom, kDepartment of
Cardiology, Hospital Clinic, University of Barcelona, Barcelona, Spain, {Yonsei University Severance
Hospital, Seoul, Korea, #Pima Heart Physicians, PC, Tucson, Arizona, **Boston Scientiﬁc
Corporation, St. Paul, Minnesota, and ††Duke University Medical Center, Durham, North Carolina.
BACKGROUND The value of antitachycardia pacing (ATP) in the
overall cohort of primary prevention patients who receive implantable cardioverter-deﬁbrillators (ICDs) remains uncertain. ATP success reported in prior trials potentially included a large number of
patients receiving unnecessary ATP for arrhythmias that may have
self-terminated owing to the prematurity of the intervention.
Although some patients derive beneﬁt from initial ATP in terminating rapid ventricular arrhythmias and thereby preventing
shocks, there are limited data allowing us to identify those patients a priori.
OBJECTIVE The purpose of APPRAISE ATP is to understand the role
of ATP in primary prevention patients currently indicated for ICD
therapy in a large prospective randomized controlled trial with modern programming parameters.
METHODS The study is a global, prospective, randomized, multicenter clinical trial conducted at up to 150 sites globally, enrolling
approximately 2600 subjects The primary endpoint of the trial is
time to ﬁrst all-cause shock in a 2-arm study with an equivalent
study design in which the incidence of all-cause shocks will be

Background
Multiple randomized controlled clinical trials, registries, and
observational studies have indicated that patients at risk for
sudden cardiac death (SCD) with reduced left ventricular
ejection fraction (LVEF) and heart failure enjoy a survival
beneﬁt from implantable cardioverter-deﬁbrillators (ICD) as
a primary prevention strategy. An ICD is capable of terminating potentially lethal ventricular arrhythmias by shock, antitachycardia pacing (ATP), or both. The frequency, timing, and
Address reprint requests and correspondence: Dr Claudio Schuger,
Department of Cardiac Electrophysiology, Henry Ford Heart & Vascular
Institute, 2799 W Grand Blvd, Detroit, MI 48202. E-mail address:
cschuger@gmail.com.

compared between primary prevention subjects programmed
with shocks only vs subjects programmed to standard therapy
(ATP and shock).
RESULTS An Electrogram and Device Interrogation Core Laboratory will review interrogation data to determine primary endpoints that occur in APPRAISE ATP. Their decisions are based
on independent physician review of the data from device interrogation.
CONCLUSION The ultimate purpose of the study is to aid clinicians
in the selection of ICD technologies based on hard endpoint evidence across the spectrum of indications for primary prevention implantation.
KEYWORDS ICD; Primary prevention; VT
(Heart Rhythm O2 2021;2:405–411) © 2021 Heart Rhythm Society.
Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

mode of termination of these ventricular arrhythmias have a
direct impact on the quality of life of ICD recipients. ICD
programming is aimed at minimizing device shocks by
preventing inappropriate therapies, avoiding unnecessary
interventions in self-terminating ventricular arrhythmias (by
delaying interventions and choosing appropriate rate cutoffs),
and maximizing the utility and efﬁciency of ATP. The advent
of the subcutaneous ICD, which avoids some of the potential
complications of endovascular devices but currently lacks
ATP capabilities, highlights the need to identify appropriate
subgroups of primary prevention cohorts that will be better
served by subcutaneous or endovascular devices, or in a
not-so-distant future by the addition of ATP modules to
subcutaneous devices.

2666-5018/© 2021 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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KEY FINDINGS
-

-

The purpose of APPRAISE ATP (Assessment of Primary
Prevention Patients Receiving an ICD – Systematic
Evaluation of ATP) is to understand the role of antitachycardia pacing (ATP) in primary prevention patients
currently indicated for implantable cardioverterdeﬁbrillator (ICD) therapy in a large prospective
randomized controlled trial with modern programming
parameters.
The primary endpoint of the trial is time to ﬁrst all-cause
shock in a 2-arm study with an equivalent study design
in which the incidence of all-cause shocks will be
compared between primary prevention subjects programmed with shocks only vs subjects programmed to
standard therapy (ATP and shock).

-

APPRAISE ATP is a global, prospective, randomized,
multicenter clinical trial. The study will be conducted
at up to 150 sites globally, enrolling approximately
2600 subjects followed for a minimum of 18 months.

-

The conclusions of the trial would then inform clinical
decision-making regarding the selection of ICD technologies and ATP availability and programming based
on hard endpoint evidence across the spectrum of indications for primary prevention.

Termination by ATP of fast ventricular tachycardia
in secondary prevention patients
ATP was originally developed to terminate macroreentrant
ventricular arrhythmias by interfering with the propagation
and/or refractoriness of some portion of the tachycardia circuit.
Pace termination success is limited by the conduction time to
the circuit, the size of the excitable gap, and the ventricular
refractoriness of intervening tissue and circuit alike. Given
these factors, it was originally believed that termination by pacing was increasingly difﬁcult as the tachycardia cycle length
(CL) shortened, and its use was most effective with secondary
prevention ICD recipients with relatively slow tachycardias.1
Success in terminating slow ventricular tachycardia (VT) was
achieved in approximately 90% of patients. In 2%–4% of patients, however, ATP accelerated VT into ventricular ﬁbrillation (VF) zones, requiring a shock for arrhythmia termination.
The PainFREE Rx trial was an observational study to
evaluate the use of empiric ATP in fast VT (FVT) in a secondary prevention population.2 They analyzed 1100 episodes
in 65 patients, of which 446 (40%) were classiﬁed as FVT
(.240 and ,320 ms CL) and 57% had slower VTs and
3% VF. They observed FVT termination after 1 ATP
sequence in 85% of cases. A sequence of 8 beats at 88%
CL was the initial sequence, followed by a second burst at
88% CL minus 10 ms, which raised the success rate to
89%. The median duration of FVT episodes terminated by
ATP was ,6 seconds, while those requiring shocks for failed
ATP sustained for a median of 21 seconds before receiving a

shock. Interestingly, there was a statistically signiﬁcant difference in the history of nonsustained VT among those patients in which ATP was successful to terminate FVT. The
authors acknowledged in the discussion that the high efﬁcacy
of ATP in terminating FVT might have been in part owing to
the possibility that they were treating self-terminating VTs,
which led to the design of a subsequent randomized trial.
PainFREE Rx II3 was a multicenter, randomized study
comparing the use of ATP vs shock as ﬁrst treatment for
FVT as deﬁned in the prior study. Patients were randomized
to receive 1 ATP sequence followed by shock or shocks
only, with both arms programmed to detection of 18 of 24
fast intervals at a rate cutoff of 188 beats per minute (bpm).
This study enrolled patients from January 2001 to March
2002 and included patients with secondary indications. ATP
was found to have successfully terminated 229 of 284 episodes
of FVT (81% unadjusted, 72% after adjusting for multiple
events). In the ATP arm 57 episodes were treated by shocks,
compared to 99 episodes treated by shocks in the shock-only
arm. The number of patients receiving shocks in each arm
was not reported. Only 43% of episodes were adjudicated for
analysis, given the memory limitation of device storage. Allcause mortality was 10% in the ATP arm and 7% in the
shock-only arm. Over one-third of episodes in the shock arm
self-terminated during a median 3.3-second capacitor charge
time, leading to the possibility that longer detection times could
further reduce the rate of ATP and/or shocks for VT. Although
it is likely that ATP therapy reduced the number of shocks in a
secondary prevention population, the short detection times and
the committed nature of shocks used in both PainFREE RX
trials did not eliminate the confounding effects of selfterminating episodes that would otherwise require no therapy,
and potentially increased the number of shocks in the shockonly arm as compared to the ATP arm. Despite these caveats,
the PainFREE trials demonstrated the utility of ATP in terminating FVT in secondary prevention cohorts.

Primary prevention indications trials with
secondary prevention programming
The MADIT,4 MADIT II,5 and SCD-HeFT6 trials expanded
indications for use of ICDs beyond those patients with a history of VT/VF to those at risk of developing a ventricular
tachyarrhythmia. MADIT II allowed physicians to program
devices according to investigator discretion. In SCD-HeFT,
devices were programmed to deliver shocks alone and the
use of ATP was not permitted. These studies did not provide
medical evidence to help guide the use of ATP, rate cutoffs,
or therapy delays in primary prevention populations. Thus,
appropriate programming in primary prevention cohorts remained undeﬁned when primary prevention indications
were approved. Thus, legacy secondary prevention programming guidelines were used in primary prevention cohorts,
which resulted in high frequency of inappropriate or unnecessary therapies relative to appropriate device use.7–9 It
became clear that intelligent, speciﬁc programming was
needed for primary prevention patients.
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Primary prevention programming trials
10

The PREPARE study was a 1-armed observational study
that evaluated the effect of prolonged detection intervals in
primary prevention patients compared to historical controls.
Patients were programmed to a detection interval of 30 of
40 fast beats with a rate cutoff of 182 bpm. The authors reported a signiﬁcant reduction in the morbidity index (a composite of all-cause shocks, syncope of arrhythmic origin, and
untreated sustained symptomatic VT/VF events), from 0.26
events/year in the PREPARE cohort, as compared to 0.69
events/year in the historical cohort (P 5 .003).
The ADVANCE III11 study tested the hypothesis that
further prolongation of the delay prior to initiating therapy
may reduce ICD therapies, consisting of both shock and
ATP delivery. Patients were enrolled from March 2008 to
December 2010 and included both secondary and primary prevention patients (25% and 75%, respectively). Patients were
randomized to ATP delivery with standard detection (18/24 intervals) vs ATP delivery with long detection (30/40 intervals)
with a rate cutoff of 188 bpm in both arms. Assuming a ventricular tachyarrhythmia with a 300 ms CL, this analysis
compared a 5.4-second to a 9.0-second delay. After an average
follow-up interval of 12 months, the authors reported a 37%
reduction in the incidence of a composite of shock and ATP
therapies (P , .001) that was driven predominantly by a
42% reduction in the incidence of ATP alone (P , .001). In
the treatment arm, 3% of patients received appropriate ATP
and no shocks. The reduction in the incidence of shocks
approached but did not achieve statistical signiﬁcance (23%,
P 5 .06). No stratiﬁcation between primary and secondary
prevention patients was reported. The authors concluded that
a strategy of prolonged device detection signiﬁcantly reduced
the rate of ICD therapies.
MADIT-RIT was the ﬁrst randomized programming trial
in a homogeneous primary prevention population and
compared conventional programming with either high-rate
cutoff therapy (.200 bpm) or delayed therapy (60 seconds
between 170 and 200 bpm and 12 seconds between 200
and 250 bpm).12 Both strategies were very successful in
reducing the risk of inappropriate ICD therapy (ATP or
shock), with high-rate therapy associated with a 79% reduction (P , .001) and delayed therapy associated with a 76%
reduction (P , .001) in inappropriate therapies.
Interestingly, examination of appropriate ATP delivered in
MADIT-RIT revealed 446 therapy events in the conventional
programming arm, compared to 113 events in the high-rate
therapy arm and 143 events in the delayed therapy arm. The
authors noted that this ﬁnding suggested that much of the
ATP delivered in the conventional programming arm was prematurely delivered for nonsustained ventricular tachyarrhythmias and was therefore clinically unnecessary. Syncopal
events were equally distributed among all therapy arms. Moreover, the conventional therapy arm was associated with a statistically signiﬁcant increase in all-cause mortality when
compared to each of the novel programming arms. An analysis
of mortality in MADIT-RIT revealed a statistically signiﬁcant
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association between ATP (mostly inappropriate delivered
ATP) and all-cause mortality (hazard ratio 5 3.25, 95% conﬁdence interval 1.33–7.94, P 5 .01) while no association was
found between appropriate ATP and all-cause mortality
(hazard ratio 5 1.02, 95% conﬁdence interval 0.36–2.88,
P 5 .977).13 The association does not necessarily imply
causality but suggested that further investigation into ATP in
primary prevention populations is warranted.
A recently published sub-study of MADIT-RIT aimed to
evaluate the therapy distribution for adjudicated VA  200
bpm among the 3 arms of the study.14 The only difference between programming arms in the 200–250 bpm zone was therapy delay (1, 2.5, and 12 seconds, respectively, after
conﬁrmed detection). In all arms, therapy started with a
sequence of ATP followed by shock. Above 250 bpm all patients received shocks with no preceding ATP, as shown in
Figure 1. This study revealed a statistically signiﬁcant reduction of ATP interventions for VA  200 bpm with therapy delays up to 12 seconds, suggesting that most VT events were
self-terminating. Initial therapy was ATP in 10.5% in the conventional arm compared to 4.2% and 2.5% in high-rate and delayed programming arms (Figure 1). Most strikingly, despite
this difference in initial ATP therapy, ﬁnal shock therapy
rate was similar in all arms, suggesting that the value of
ATP in terminating rapid ventricular arrhythmias may have
been overestimated in past trials owing to the prematurity of
the intervention in otherwise self-terminating arrhythmias.

APPRAISE ATP study
We conclude from these data that the value of ATP in the
overall cohort of primary prevention patients who receive
ICDs remains uncertain. ATP success reported in prior trials
potentially included a large number of patients receiving unnecessary ATP for arrhythmias that may have self-terminated
owing to the prematurity of the intervention. Although some
patients derive beneﬁt from initial ATP in terminating rapid
ventricular arrhythmias and thereby preventing shocks, there
are limited data allowing us to identify those patients a priori.
The purpose of APPRAISE ATP is to understand the role
of ATP in primary prevention patients currently indicated for
ICD therapy in a large prospective randomized controlled
trial with modern programming parameters. This knowledge
would then inform clinical decision-making regarding the selection of ICD technologies based on hard endpoint evidence
across the spectrum of indications for primary prevention.
The primary endpoint of the trial is time to ﬁrst all-cause
shock in a 2-arm study with an equivalent study design in which
the incidence of all-cause shocks will be compared between
primary prevention subjects programmed with shocks only
vs subjects programmed to standard therapy (ATP and shock).

Study design
Assessment of Primary Prevention Patients Receiving an
ICD-Systemic Evaluation of ATP (APPRAISE ATP;
ClinicalTrials.gov Identiﬁer: NCT02923726) is a global,
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Figure 1

MADIT-RIT ventricular arrhythmias occurring above 200 beats per minute (bpm). ATP 5 antitachycardia pacing.

prospective, randomized, multicenter clinical trial. The study
will be conducted at up to 150 sites globally, enrolling
approximately 2600 subjects. Institutional review board
approval at each participating institution will be obtained in
compliance with ethical guidelines, prior to patient enrollment. Subjects will be consented for follow-up visits through
60 months. Their length of participation will differ depending
on when they entered the study.
The study will conclude after the earliest of 1 of following
occurrences: (1) 1 arm is determined to be superior at 1 of the
3 interim analyses, or (2) a number of adjudicated shock episodes have occurred to sufﬁciently power the primary
endpoint. Under current assumptions, it is expected that the
last enrolled patient will be followed for approximately 18
months and the ﬁrst enrolled patient will be followed for
approximately 60 months. The study ﬂow, data collection,
and patient follow-up are illustrated in Figure 2.

Endpoints
The primary endpoint collected postrandomization is time to
ﬁrst all-cause shock.
The secondary endpoints are:





Time to ﬁrst all-cause shock or death from any cause
Time to death from any cause
Time to ﬁrst appropriate shock
Time to ﬁrst inappropriate shock

The tertiary objective is a multivariate analysis to determine covariates associated with the use of ATP, bradycardia

pacing, and the need for future cardiac resynchronization
therapy pacing therapy.

Study population
The study population for the APPRAISE ATP trial consists
of patients who meet the guidelines15 for ICD therapy for primary prevention patients.
Patients may be included with a prior myocardial infarction and LVEF  30%, or LVEF  35% and NYHA class
II or III (ischemic or nonischemic cardiomyopathy). Key
exclusion criteria are history of spontaneous sustained VT
(160 bpm at 30 seconds in duration) or VF not due to a
reversible cause, NYHA class IV documented in medical records 90 days prior to enrollment, scheduled cardiac resynchronization therapy implant, previous subcutaneous ICD,
existing transvenous ICD device implanted for greater than
60 days, coronary artery bypass graft or percutaneous coronary intervention 90 days prior to enrollment, documented
myocardial infarction within 90 days prior to enrollment,
on the active heart transplant list, current or scheduled to
receive ventricular assist device, life expectancy shorter
than 18 months owing to any medical condition, currently
requiring hemodialysis, and known to be pregnant or plans
to become pregnant over the course of the trial.

Programming
Each arm will be programmed to 3 tachycardia detection
zones. Zones 1 (monitor) and 3 (VF) are the same in each
arm, while zone 2 (VT) is programmed to ATP and shock

Schuger et al
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Figure 2 APPRAISE ATP study design. ATP 5 antitachycardia pacing; bpm 5 beats per minute; SOC ECG 5 standard-of-care electrocardiogram;
VF 5 ventricular ﬁbrillation; VT 5 ventricular tachycardia.

or shock only (Table 1 and Figure 3). Programming is aligned
with the current 2015 HRS Consensus guidelines – Manufacturer Speciﬁc Translation of the HRS Consensus16,17:
VT Zone: 200 bpm, 12-second delay, ATP ! 1 burst of
8 pulses at 84% CL followed by 41 joule shock if necessary,
vs no ATP and 41 joule shock.
VF Zone: 250 bpm, 5-second delay, 41 joule shock.

Statistical methods and sample size calculation
The study was designed to show that the absence of ATP
therapy in a primary prevention ICD cohort is not only noninferior but equivalent to devices delivering ATP by
measuring the incidence of all-cause shock. Noninferiority
and equivalence appear to be used interchangeably in the
medical literature but have speciﬁc meanings:
 Noninferiority indicates that the new treatment is no
worse than the reference treatment by some margin that
represents a difference that is clinically meaningful;
may be used for a treatment that is cheaper or easier to
administer.
Table 1

Programming by randomized arm
Arm 1: ATP and shock

Zone 1 (VT-1)
Zone 2 (VT)

Zone 3 (VF)

Arm 2: shock only

170 bpm monitor only
200 bpm, 12-second
200 bpm, 12-second
delay
delay
41 J shock
ATP (1 burst of 8
pulses, 84% CL)
41 J shock
250 bpm, 5-second delay, 41 J shock

ATP 5 antitachycardia pacing; bpm 5 beats per minute; CL 5 cycle
length; VF 5 ventricular ﬁbrillation; VT 5 ventricular tachycardia.

 Equivalence indicates that the new treatment is no better
and no worse than the reference treatment by some
margin (6 delta) that represents a difference that is clinically meaningful.
The hazard ratio of all-cause shocks will be used to evaluate
the equivalence of shock-only programming vs standard (ATP
and shock) therapy. A relative equivalence margin (delta) of
35% in each direction will be employed, resulting in an equivalence region ranging from 0.65 to 1.54 (1/0.65). The
APPRAISE ATP steering committee selected this equivalence
region because it represented a clinical margin of indifference
that could be studied with a reasonable number of subjects and
duration of follow-up. The following hypotheses will be used
to test the primary endpoint:
H0: hazard ratio  0.65 or hazard ratio  (1/0.65)
HA: 0.65 , hazard ratio , (1/0.65)
A total of at least 2600 randomized subjects—1300 per
group—will be required to sufﬁciently power the primary
endpoint. The sample size of 2600 subjects will provide
the 284 subjects with a shock therapy episode necessary
to power the primary endpoint. The following assumptions
were used to determine the required number of primary
endpoint shock therapy events: shock rate of 6%–7% at
18 months; attrition rate owing to death, withdrawal, or
loss to follow-up of 10% at 18 months; 5% type I error/
alpha and 90% power.
All randomized subjects will contribute to the analysis of
the primary endpoint. Cox proportional hazards modeling
will be performed with time to ﬁrst shock therapy episode
used as the outcome and programming scheme used as the
covariate in the model. Traditional therapy (ATP and shock)
will be considered the reference group in the analysis. Each
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Figure 3 Programming of zones 2 and 3 of the trial, with estimated times to therapy. ATP 5 antitachycardia pacing; VF 5 ventricular ﬁbrillation; VT 5 ventricular
tachycardia.

subject’s ﬁrst shock therapy episode will contribute to the
analysis. Subjects without a shock therapy episode will be
censored at their date of death, withdrawal, or study exit, or
on the date of the data snapshot, whichever occurs ﬁrst. If
the conﬁdence interval for the hazard ratio is fully contained
within the equivalence region—between 0.65 and 1.54—
equivalence of shocks only and standard programming will
be concluded.
If equivalency cannot be established, further testing for
superiority will be performed without need for a multiplicity
adjustment to the signiﬁcance level of the test beyond the
adjustment necessary to accommodate the interim superiority
tests. This additional testing is possible because the equivalence test is composed of 2 separate 1-sided noninferiority
tests. If noninferiority is established for only 1 of the 2 1sided noninferiority tests, superiority can further be tested,
per gating methodology (Figure 4).

Planned interim analyses
Despite the overall hypothesis of equivalency for the study,
interim superiority analyses were designed to identify the
scenario in which the shock rates signiﬁcantly differed between the 2 groups. Four analyses (3 interim analyses and
1 ﬁnal) will be performed, occurring after approximately
71, 142, 213, and 284 primary endpoint events have been
observed. The overall study type I error/alpha will be maintained at 5% through use of an O’Brien-Fleming-type error
spending function.

Subgroup analyses
Analyses will be performed to assess whether signiﬁcant interactions exist between randomization group and various
baseline characteristics. Analyses will evaluate, but are not
limited to, baseline characteristics subgroups by gender,
ischemic status, diabetes, and age 65 or ,65.
Regardless of the results of the interaction test for each
characteristic, analyses of each subgroup will be performed.
Analyses will be conducted for the primary endpoint and all
secondary endpoints.

Core lab and event adjudication
An Electrogram and Device Interrogation Core Laboratory
will review interrogation data to determine primary endpoints
that occur in APPRAISE ATP. Their decisions are based on
independent physician review of the data from device interrogation. The Duke Clinical Research Institute Arrhythmia
Core Lab (ACL) is responsible for study event adjudications.
The ACL reviewers will be composed of a panel of physicians who have expertise in cardiovascular medicine and
clinical cardiac electrophysiology. No sponsor representative
will serve as an ACL reviewer.
The ACL Committee will review and adjudicate
arrhythmia events for the following:





All-cause ICD therapies
Appropriate ICD therapies
Inappropriate ICD therapies
Sustained arrhythmias without therapy

Every event that meets these criteria will be adjudicated
until the primary endpoint is met.

Discussion

Figure 4 Possible outcomes of the APPRAISE ATP study: equivalence,
noninferior, superior, inconclusive. ATP 5 antitachycardia pacing.

The retrospective analysis of the MADIT-RIT cohort for
appropriate therapies at or above 200 bpm demonstrated
that increasing therapy delays resulted in marked reductions
in the utilization of ATP therapies as the time to therapy was
increased from 3.4 seconds (arm A) to 4.9 seconds (arm B) to
14.4 seconds (arm C).14 Furthermore, analysis of the 2 types
of ICD therapies (ATP or shock) revealed that the incidence
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of appropriate shocks delivered for ventricular arrhythmias
200 bpm was similar across all 3 arms, with no signiﬁcant
differences. These ﬁndings altogether suggested a limited
value of ATP for treating fast ventricular arrhythmias 200
bpm once modern programming with longer detection delays
was applied in primary prevention ICD populations as
opposed to ATP great efﬁcacy in secondary prevention populations with documented VT.
The only plausible explanation for the above observations
is that as therapy delay is increased, many of the ventricular
arrhythmias self-terminate; hence the value of ATP effectiveness in a primary prevention population could be overestimated. Moreover, MADIT RIT and ADVANCE III study
results demonstrated that relatively long therapy delays are
well tolerated, without an increase in cardiovascular
morbidity, while enormously reducing the frequency of unnecessary interventions, mainly ATP.
We surmise from the data that the value of ATP in
primary prevention ICD patients may have been overestimated in earlier studies owing to the prematurity of
the intervention. Considering these ﬁndings, a substantially larger prospective randomized controlled trial is
necessary to reassess the value of ATP in primary prevention cohorts. Given that inappropriately delivered
ATP has been associated with increased mortality and
that the value of ATP maybe limited to a speciﬁc subset of patients, APPRAISE ATP has been designed to
identify such cohorts and ascertain in a large clinical
trial with modern programming parameters if ATP
should be available to all patients. The result of this
trial will aid clinical practice as to appropriate selection
of the right device platform for different subsets and
establish when ATP is likely to be of value or potentially detrimental.
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